NIFTY : 14,823.15 SENSEX : 48,949.76 USDINR : 73.67 GOLD : 47,785.00
Support: +91 265 2361474
  • Equity
  • Mutual Fund
  • Derivatives
  • Commodity
  • IPO
  • Other Market

Corporate News

As on 04-May-2021  15:35

Bajaj Healthcare launches “Favijaj” (Favipiravir) for treatment of Covid-19
Bajaj Healthcare announced the launch of “Favijaj” (Favipiravir) an antiviral drug used for treating patients suffering from influenza virus and has proved to be effective over COVID patients. BHL has received approval from India's drug regulator, to manufacture and market “Favijaj” the oral Favipiravir approved medication in India for the treatment of COVID-19 from 4 May 2021.

“FAVIJAJ” tablets comprising Favipiravir in different dosage forms is used for the treatment of mild to moderate Covid-19 disease. Favipiravir is an antiviral drug, which has shown potent in vitro activity against severe acute respiratory syndrome of coronavirus.

Powered by Capital Market - Live News

Copyright © 2019 VSE Stock Services Limited (“VSSL”). All Rights Reserved Developed and powered by CMOTS Infotech ( ISO 9001:2015 certified )